Bonesupport: A more detailed look at the Q4 report - Redeye

Redeye returns with a more in-depth take on BONESUPPORT’s Q4-report following the conference call and management discussion. We are prone to minor downwards adjustments to our sales expectations in the coming quarters, though non-affecting our Base Case, which entails a c.80% upside potential. We believe the stock could soon be re-ignited by a potential FDA approval in the coming weeks.

Länk till analysen i sin helhet: https://www.redeye.se/research/833487/bonesupport-a-more-detailed-look-at-the-q4-report?utm_source=finwire&utm_medium=RSS